Clinical trial · no report yet · Phase 2
NCT04115631
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
- NCT04115631 ↗
- Active not recruiting
- ECOG-ACRIN Cancer Research Group
- 8 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 4 | |
| Podcasts | 3 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Liver Lymphoma; Mantle Cell Lymphoma
- Interventions
- Acalabrutinib; Bendamustine; Bendamustine Hydrochloride; Cytarabine; Rituximab
- Arms
- Arm A (bendamustine, rituximab, cytarabine) · Experimental
- Arm B (acalabrutinib, bendamustine, rituximab, cytarabine) · Experimental
- Arm C (acalabrutinib, bendamustine, rituximab) · Experimental
- Enrollment
- 360
- Primary outcomes
- Composite of positron emission tomography (PET)/computed tomography (CT) complete response (CR) and peripheral blood (PB) minimal residual disease (MRD) negative rate
- Sponsor
- ECOG-ACRIN Cancer Research Group with National Cancer Institute (NCI)
- Start
- Dec 13, 2019
- Primary completion
- Dec 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04115631 · updated Sep 14, 2026
Publications
linked from the registry- Patel DA, Wan F, Trinkaus K, Guy DG, Edwin N, Watkins M, Bartlett NL, Cashen A, Fehniger TA, Ghobadi A, Shah NM, Kahl BS. Bendamustine/Rituximab Plus Cytarabine/Rituximab, With or Without Acalabrutinib, for the Initial Treatment of Transplant-Eligible Mantle Cell Lymphoma Patients: Pooled Data From Two Pilot Studies. Clin Lymphoma Myeloma Leuk. 2023 Jul;23(7):552-560. doi: 10.1016/j.clml.2023.04.003. Epub 2023 Apr 24. PubMed 37183115